Under pathological conditions, the Janus kinase (JAK)/STAT signaling pathway can regulate the proliferation, differentiation and migration of tumor cells, including colorectal cancer (CRC). CRC is the third major types of cancer among males and the second among females worldwide. In China, CRC is the fifth common cancer among both males and females. Western blotting, flow cytometry, RNA interference, immunoprecipitation, xenografts models, and immunohistochemical staining were carried out to evaluate the possible mechanisms of acton of ruxolitinib. The present data suggested that ruxolitinib can suppress CRC cell proliferation by inducing apoptosis. Firstly, JAK1/2-STAT1 was identified as the target of ruxolitinib. Then, ruxolitinib downregulated myeloid cell leukemia-1 (Mcl-1) mRNA level and decreased its protein level, which enabled Bak to trigger CRC apoptosis. Furthermore, ruxolitinib exerted potent activity against CRC xenograft growth in vivo. High expression of phosphorylated STAT1 (S727) was also confirmed in 44 pairs of human colon carcinoma and adjacent normal tissues. Taken together, the results showed that ruxolitinib decreased JAK1/2-STAT1-Mcl-1 protein level and effectively suppressed CRC cell proliferation in vitro and in vivo. Therefore, ruxolitinib could be a promising anticancer agent for CRC treatment. with those who did in the Pudong New Area of Shanghai of China (hazard ratio (HR)=1.46; 95% confidence interval (CI): 1.12-1.91) (3-5). Nevertheless, ~40% of patients who undergo surgery, which is applied in combination with chemotherapy or radiation therapy, subsequently experience local and systemic recurrence or resistance (6). Among primary risk factors, complex genomic alterations, which are essential in the mechanism of CRC pathophysiology, may induce resistance of CRC to drug therapy, thus making CRC the fourth most common cause of cancer-associated mortality (4,7). Consequently, investigating the mechanisms underpinning CRC chemosensitivity is important to improve treatment. Under pathological conditions, the Janus kinase (JAK)-STAT signaling pathway has been shown to regulate proliferation, differentiation and angiogenesis of malignant tumor cells and to promote the development of several malignant tumors, such as breast cancer and esophageal cancer (8,9). This pathway is constitutively activated in myeloproliferative diseases and in various solid tumors, including hepatocellular carcinomas, prostate, breast, head and neck, lung and CRC (10). Although the exact dysregulation mechanism of JAK/STAT signaling in CRC remains unclear, the JAK/STAT signaling pathway has been suggested as therapeutic target for the treatment of CRC (11,12). Myeloid cell leukemia-1 (Mcl-1) has sequence and functional similarity to Bcl-2 (13). Mcl-1 has a short half-life and is a highly regulated protein (14). The upstream regulatory kinase cascades of Mcl-1 transcription include JAK/STAT, PI3K and mitogen-activated protein kinases (15). Previous studies have suggested that Mcl-1 may have a significant part in th...